On November 8, 2022 MGFB, a subsidiary of FairWinds Bio (FWB), reported that it has entered into a patent license agreement with Mayo Clinic to advance experimental cancer vaccine therapeutics based on a novel platform developed over the past 20 years by Richard Vile, Ph.D., Mayo Clinic Professor of Immunology as well as several colleagues (Press release, Greenfire, NOV 8, 2022, View Source [SID1234625113]). Founding equity ownership in MGFB includes FWB, University of Leeds and Mayo Clinic.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The platform is designed to address mutational burden, immune escape, and tumor resistance, commonly seen in many solid tumor patients. By delivering a broad repertoire of tumor associated antigens, ASEL and neoantigens enhanced by APOBEC mutagenesis, strong T-cell responses have been demonstrated pre-clinically without the need for identification of patient specific tumor associated antigens. Preclinical studies have demonstrated durable responses in a melanoma study in mice. Additional pre-clinical data in models of glioma and hepatocellular carcinoma confirm the utility of this approach. MGFB intends to advance multiple programs into the clinic to address indications where current therapeutic options are limited.
"I look forward to working with the MGFB team to advance these therapeutic vaccines to help the many patients who need better treatment options than are currently available," said Dr. Vile.
"We are very excited to collaborate with Mayo Clinic on this approach to treating solid tumors. Our objective is to develop the most therapeutically effective constructs with the hope of providing patients better therapeutic alternatives," said Ajit Gill, CEO of MGFB.
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.